Behc¸et's disease (BD) is a multisystem vasculopathy with a worldwide distribution [1] . There is currently no available laboratory test or characteristic histology by which a patient with the disorder may be identified. A presumptive diagnosis rests on the presence of a constellation of pathological features and their associated clinical symptomatology. Pathologically, there are three important vascular abnormalities: perivascular lymphocyte cuffing, transmural polymorphonuclear infiltration and spontaneous intravascular thrombosis. Hippocrates in the 5th century described the salient features of the clinical aspects of the disease and, in particular, painful ulceration of the mucosa lining the mouth and genitalia [2] . Behc¸et in 1937 highlighted the link between this and inflammation of the eye; more recently sets of diagnostic criteria incorporating these as well as other associated symptoms and signs have evolved to facilitate recognition of the disorder [3] .
However, because of the broad nature of the vascular pathology and multisystem involvement, and geographical differences in the clinical presentation of BD, these criteria are wide ranging and uncertainty exists as to how broadly based the individual patient's clinical syndrome has to be to rank with the condition [4] .
Consensus would have that BD is a genetically determined autoimmune condition owing to the strong association with HLA-B51 [1] . However, there are uncertainties as to the contribution made by genetic factors, because of the variation in the prevalence of HLA-B51 in different populations. Equally, there are aspects which present difficulty in accepting an autoimmune aetiology, since there is a lack of evidence for a humoral component in the autoimmune response, circulating autoantibodies being identifiable only in a minority of patients.
Without defined pathogenetic mechanisms, the treatment of Behc¸et's disease has evolved empirically; relatively few controlled studies exist and morbidity as well as mortality due to the disorder remain substantial. Current therapies aim to suppress immune responses with corticosteroids and azathioprine, to modulate cytokine dysregulation with interferon-and thalidomide or control inflammation and hypothetical infection [5] [6] [7] [8] [9] [10] . Several lines of evidence point to the contribution of T-cell autoreactivity to the pathogenesis of BD. In addition to the MHC association, oligoclonal expansion of a restricted repertoire of T-cell Va and Vb genes correlates with active disease, T cells specific for the autoantigen, heat shock protein 60, have been identified from BD patients, and BD responds to therapy with calcineurin antagonists [11] [12] [13] .
Lymphocyte depletion with antithymocyte globulin has led to remission in BD, but this approach is limited by the development of an antiglobulin response [14, 15] . Humanized monoclonal antibodies avoid antiglobulin responses of clinical significance, allowing repeated dosing, which is of importance in relapsing autoimmune disease. The CD52 antigen is present on lymphocytes and macrophages, but the predominant effect of anti-CD52 antibody therapy (CAMPATH 1-H) is T-cell depletion where recovery of the CD4þ subset is usually delayed and incomplete [16] . CAMPATH 1-H is capable of inducing sustained treatment-free remission in other immune vasculopathies, including polyarteritis and Wegener's granulomatosis, as well as in rheumatoid arthritis, multiple sclerosis and inflammatory eye disease [16] [17] [18] [19] [20] . We have investigated the use of CAMPATH-1H in 18 patients referred to us with stigmas which qualified them for a presumptive diagnosis of Behc¸et's disease.
Patients and methods

Patients
Eighteen patients were recruited from the vasculitis clinic at Addenbrooke's hospital and received CAMPATH-1H after giving informed consent. Thirteen were female; the mean age was 37 yr (range: 18-61) ( Table 1) . They were all Caucasian, 16 were born in the UK, one in the USA and one in Canada. The average prior disease duration was 78 months (range: 1-354). All patients had had episodes of recurrent oral and genital 
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ulceration and met international criteria for BD [3] . In addition, there was evidence from non-invasive imaging of active inflammation in at least one other system commonly involved in BD in 15/18 (83%), and supportive histology from an affected organ in 15/18 (83%). The pathergy phenomenon was observed in 9/18 (50%). Autoimmune serology was negative for antinuclear antibodies, rheumatoid factor, antineutrophil cytoplasmic antibody (ANCA) ELISAs for proteinase 3-ANCA and myeloperoxidase-ANCA, cryoglobulins and anticardiolipin antibodies [21, 22] . No patient had evidence of hepatitis B, hepatitis C or human immunodeficiency virus infection. Thirteen had failed steroid, immunosuppressive and other therapies, while five had received previous steroids but had not had immunosuppressive therapy (Table 1) .
Treatment with anti-CD52 
Organ involvement
The pattern of organ involvement before entry and at the time of CAMPATH-1H is listed (Tables 1, and 2 ). Twelve (67%) had had uveitis, and in four there was active ocular inflammation at the time of entry (patients 1, 6, 13 and 15). Neuropsychiatric involvement had been present in 12 (67%), joint involvement in 13 (70%), skin involvement in 12 (67%) and involvement of the gastrointestinal tract in seven (39%). Less common features were cardiac and pulmonary involvement in three each (16%), and renovascular involvement in two (11%). Twelve patients were entered with frequently relapsing disease with the aim of reducing their cumulative steroid or immunosuppressive therapy. Six presented acutely, two with life-threatening multiple organ infarcts (patients 5 and 12), two with gastrointestinal vasculitis and haemorrhage (patients 1 and 2), and two with disturbed cerebral function (patients 9 and 11).
Investigations
Sequential evaluation of haematological and biochemical indices included C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and CD4þ T-cell levels. They were performed prior to and at 3, 6, 9 and 12 months after CAMPATH-1H.
Imaging. After the risk of infection had been excluded, standard techniques were employed to image sites of possible inflammation, including autologous leucocyte scintiscanning, MRI with enhancement, bone scan with tomography, angiography and cranial single photon emission computed tomography (SPECT).
Statistics
Laboratory variables are expressed as mean ± standard deviation and other continuous variables are described as median and range. For comparison of results before and after treatment with CAMPATH-1H, such as CRP and ESR, data series were assessed by two-tailed t-test after logarithmic conversion.
Results
Disease activity
Remission. Three months after treatment with one course of CAMPATH-1H, eight patients had lost all features of disease activity and seven had a partial (Table 2) . Follow-up. The duration of follow-up averaged 37 months (range: 6-60). Relapses were seen in seven of the 13 (54%) entering remission with CAMPATH-1H, after an average of 25 months (range 12-39) (Figure 1 ). In two, retreatment with CAMPATH-1H led to further remission, other relapses were treated by an increase in prednisolone with reintroduction of immunosuppressives in two. Patient 1 died at 60 months of a cardiovascular event while in stable remission. Of the five in partial remission at 6 months, three had inactive disease on continued treatment while two had persistent, grumbling disease.
Immunosuppressive drugs
Prednisolone doses were reduced from an average of 17.7 (range: 0-60) mg/day before treatment to 6.8 (0-20) mg/day at 3 (P < 0.005), 4.7 (0-20) mg/day at 6 (P < 0.005), and 2.8 (0-10) mg/day by 12 months (P < 0.005) (Figure 2 ). Cyclosporin was reintroduced in four patients to control persisting or relapsing disease. Patient 17 had a partial remission after CAMPATH-1H and full remission followed mycophenolate mofetil. Concomitant treatment with plasma exchange (patient 14) , and anti-CD18 monoclonal antibodies and prostacyclin (patients 5 and 12) was used in order to achieve rapid control of fulminant disease [24] . There were no adverse effects associated with these additional interventions and disease activity was controlled without further agents.
Laboratory markers
There were non-significant falls in CRP at 3 and 6 months; the ESR at 6 months was lower than at the time of treatment (P ¼ 0.007) ( Table 3 ). Platelet counts were lower after treatment but remained in the normal range. The most dramatic changes were in lymphocyte and CD4þ T-cell counts after CAMPATH-1H, which remained markedly depressed (Table 3 and Fig. 3 ).
Adverse effects
Infusion reactions. A cytokine release syndrome occurs following CAMPATH-1H consisting of fevers, chills, *P < 0.05; **P < 0.01; ***P < 0.001. backache, wheezing and malaise [23] . Despite prophylactic measures, 5/18 (28%) experienced a moderate reaction, which abated at the end of the infusion course (Table 4) . Other adverse effects. Infections were unusual; neither reported infection was directly attributable to CAMPATH-1H or to lymphocyte depletion (Table  4) . Hypothyroidism developed in two following CAMPATH-1H and has required continued thyroxine replacement. Thyroid autoantibodies were not detectable in either patient.
Discussion
Behc¸et's disease is a multisystem vasculopathy for which there is neither a diagnostic test or characteristic biopsy histopathology. As a consequence uncertainty exists as to identification of the condition, hampering progress towards logical treatment of the disorder. This has led to the proposal of various sets of criteria by which diagnosis by consensus can be established. The most recently formulated are those put forward by the International Study Group for Behc¸et's Disease and require recurrent oral ulceration, as the major criterion and two minor criteria from amongst four, those being recurrent genital ulceration, evidence of ocular vasculitis, skin lesions or a positive pathergy test [3] . All 18 patients met these critera. Additionally, imaging studies were consistent with the presence of sites of active inflammation in 15/18 and biopsies revealed active inflammation in the absence of infection or other non-autoimmune cause in 15/18. Moreover, features consistent with the diagnosis of other common small vessel vasculopathies, such as Wegener's granulomatosis or microscopic polyangiitis, were sought and were absent. The demography of patients in this series differs from those of large cohort studies where severe disease was more common in men and cardiac and major arterial disease were more frequent [25] . Part of this difference may be explained by a selective referral policy and by differences in the geographical expression of BD; and it is possible that therapeutic responses to CAMPATH-1H will vary in other BD cohorts.
The ready response to therapeutic intervention with CAMPATH-1H was surprising. Long-term treatmentfree remission was achieved in the majority of patients, which is more striking than in other groups of patients treated with CAMPATH-1H, such as those with rheumatoid arthritis and Wegener's granulomatosis [16, 18] . The therapeutic responses in BD approached those seen in multiple sclerosis patients given first-time treatment (no new lesions but progression of previously established lesions) [19] . The control of disease after CAMPATH-1H also supports a central role of CD4þ T cells in the pathogenesis of BD, which merits further investigation.
In our patients, some with severe life-threatening disease, the treatment was generally well tolerated, with all patients completing the course of CAMPATH-1H apart from one in whom treatment was suspended owing to concurrent infection. Infusion reactions did not persist beyond the infusion period and were controlled with symptomatic treatments. Of more concern has been the prolonged lymphopenia observed after CAMPATH-1H, again noted here (Figure 3 ). Opportunistic infections were not seen although herpes simplex and fungal prophylaxis was routine. The low incidence of infections may relate to the reduction in steroid doses after CAMPATH-1H and avoiding immunosuppressives unless the clinical status deteriorated. Hypothyroidism has also occurred following the treatment of multiple sclerosis with CAMPATH-1H, but the mechanism for this promotion of thyroid autoimmunity is not understood [26] .
Our studies indicate that Behc¸et's disease may be particularly amenable to treatment with CAMPATH-1H. These observations provide clues to the pathogenesis and more specific immunotherapy for the constellation of pathologies and their related symptomatology classified eponymously as constituting Behc¸et's disease.
